HS 10506
Alternative Names: HS-10506Latest Information Update: 04 Mar 2024
At a glance
- Originator Jiangsu Hansoh Pharmaceutical
- Class Antidepressants; Sleep disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Depressive disorders; Insomnia
Most Recent Events
- 26 Feb 2024 Jiangsu Hansoh Pharmaceutical plans a phase Ib/II trial in Insomnia(In adults) in China (PO, Tablet) in March 2024 (NCT06279286)
- 12 Jul 2023 Jiangsu Hansoh Pharmaceutical plans a phase I trial (In volunteers) in China (PO) in July 2023 (NCT05953506)
- 04 May 2023 Preclinical trials in Depressive disorders in China (PO) prior to May 2023